Remove Clinical Trials Remove Life Science Remove Pharma Companies Remove Research
article thumbnail

Ontario Announces $40 Million Investment as it Aims to Become a Global Life Sciences Hub

XTalks

Ontario, Canada’s largest province by population, is stepping up its commitment to the life sciences sector with an investment of $40 million. The $40 million will come from the Venture Ontario Fund, which is dedicated to helping Ontario life sciences companies and biomanufacturers innovate, grow and compete in global markets.

article thumbnail

Top Life Science News and Trends in 2023 at Xtalks

XTalks

In 2023, there were significant advancements and notable trends in the life sciences. Xtalks compiled a list of its top life science news and trends of 2023, which provided readers with the latest developments, information and expert insights across life science industries, including pharma, biotech and medical device.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

4 Life Sciences Trends for 2023

XTalks

The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.

article thumbnail

Synthetic control arms in clinical trials: Making it happen

pharmaphorum

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. David Clifton is professor of clinical machine learning in the Department of Engineering Science of the University of Oxford. About the panel.

article thumbnail

Can technology help diversify clinical trials?

pharmaphorum

This is the second in a two-part series examining how pharma can embrace the DEI agenda to create more effective medicines through more representative clinical trials. The same principles are increasingly being applied to clinical trials to improve diversity, mitigate bias, and reinforce inclusion in clinical trials.

article thumbnail

Digital tools driving innovative clinical trials

pharmaphorum

The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the clinical trial space. Hybrid or decentralised clinical trials (DCTs) have gained traction as technology, infrastructure and knowledge have evolved to support their use. Source: Izmailova et al, 2017.

article thumbnail

Initiative to measure carbon impact of clinical trials

Drug Discovery World

A working group has been created to measure and compare the carbon footprint of centralised (traditional site-based) and decentralised clinical trials. The Clinical Trials Environmental Impact Community of Interest (CoI) was started by Pistoia Alliance member, Syneos Health. Growing pressure on life sciences.